Ocular Therapeutix
Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Launch date
Employees
Market cap
CAD1.9b
Enterprise valuation
CAD1.4b (Public information from Sep 2024)
Share price
$9.05 OCUL
Bedford Texas (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.4m | 43.5m | 51.5m | 58.4m | 66.2m | 75.0m | 95.3m |
| % growth | 312 % | 150 % | 18 % | 13 % | 13 % | 13 % | 27 % |
| EBITDA | (62.7m) | (78.0m) | (77.9m) | (75.4m) | (146m) | 1.3b | (166m) |
| % EBITDA margin | (360 %) | (179 %) | (151 %) | (129 %) | (220 %) | 1791 % | (174 %) |
| Profit | (156m) | (6.6m) | (71.0m) | (80.7m) | (180m) | (162m) | (149m) |
| % profit margin | (894 %) | (15 %) | (138 %) | (138 %) | (272 %) | (216 %) | (157 %) |
| EV / revenue | 79.3x | 9.7x | 3.3x | 8.4x | 20.8x | 18.4x | 14.4x |
| EV / EBITDA | -22.0x | -5.4x | -2.2x | -6.5x | -9.4x | 1.0x | -8.3x |
| R&D budget | 28.7m | 50.1m | 53.5m | 61.1m | - | - | - |
| R&D % of revenue | 165 % | 115 % | 104 % | 104 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.0m | Series A | |
| N/A | $6.0m | Series B | |
$15.0m | Series C | ||
$6.0m | Series C | ||
$14.0m | Series D | ||
$8.5m | Series E | ||
| N/A | N/A | IPO | |
* | N/A | $88.0m | Post IPO Equity |
| N/A | $35.1m | Post IPO Equity | |
| N/A | $37.5m | Post IPO Debt | |
* | N/A | $45.0m | Post IPO Equity |
* | N/A | $100m | Post IPO Equity |
* | $325m | Private Placement VC | |
| Total Funding | CAD512m | ||
Recent News about Ocular Therapeutix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.